Asuragen
Asuragen is a biotechnology company based in Austin, Texas involved in diagnostics and therapeutics.History
In 1989 Dr. Matt Winkler left his position as an Associate Professor of Zoology at the University of Texas and formed a molecular biology reagent company called Ambion. Winkler then formed Asuragen from Ambion's Molecular Diagnostics and Pharmacogenomic Service Divisions following the March 2006 sale of the Research Products Division of Ambion Inc. to the Applied Biosystems Group. In December 2007, the microRNA therapeutics activities were moved into a new entity called Mirna Therapeutics.
In October 2018, Asuragen announced the hiring of Tom Copa as senior vice president for commercial operations.Products and Services
Asuragen's offerings include molecular diagnostic products providing identification of genetic abnormalities associated with oncology and genetic diseases. The company also provides RNA-related services and PCR kits designed for protein detection. The company received $49 million in funding in 2006.
In 2018, Asuragen was named one of the primary producers of PCR reagents by Apex Market Reports.
